Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of LH-001 in Healthy Participants
NCT06546449Phase 1Recruiting
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LH-001 (9 arms). Primary endpoints: Percentage of participants who experience at least one treatment-emergent adverse event at 21 days, Percentage of participants who discontinue due to an adverse event at 21 days and 3 more. Started May 2025; status: recruiting.
02
Drugs
LH-001
Beyond the preview
Go deeper on NCT06546449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546449.